Enzon Pharmaceuticals Files 8-K/A on Shareholder Nominations
Ticker: ENZN · Form: 8-K/A · Filed: Jul 11, 2024 · CIK: 727510
Sentiment: neutral
Topics: corporate-governance, amendment, shareholder-meeting
TL;DR
Enzon Pharma amended its 8-K filing regarding shareholder director nominations for the upcoming annual meeting.
AI Summary
Enzon Pharmaceuticals, Inc. filed an amendment (8-K/A) on July 11, 2024, regarding shareholder nominations for its board of directors. The filing specifically addresses Item 5.03, concerning amendments to articles of incorporation or bylaws, and Item 5.07, related to the submission of matters to a vote of security holders. The amendment pertains to the company's annual meeting of shareholders.
Why It Matters
This amendment clarifies procedures and details related to shareholder nominations for Enzon Pharmaceuticals' board, impacting corporate governance and potential director elections.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and concerns procedural matters related to shareholder nominations, not a significant financial event.
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — Registrant
- July 2, 2024 (date) — Earliest event reported
- July 11, 2024 (date) — Filing date
- Delaware (location) — State of incorporation
- 20 Commerce Drive (Suite 135), Cranford, New Jersey (address) — Business address
FAQ
What specific items are being amended in this 8-K/A filing?
This 8-K/A filing amends Item 5.03 (Amendments to Articles of Incorporation or Bylaws) and Item 5.07 (Submission of Matters to a Vote of Security Holders) of the original report.
What is the date of the earliest event reported in this filing?
The earliest event reported is dated July 2, 2024.
What is the primary subject of the amendment?
The amendment concerns shareholder nominations for the company's board of directors and matters submitted to a vote of security holders.
What is the company's state of incorporation?
Enzon Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of Enzon Pharmaceuticals, Inc.?
The business address is 20 Commerce Drive (Suite 135), Cranford, New Jersey.
Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2024-07-11 17:01:02
Filing Documents
- tm2419328d1_8ka.htm (8-K/A) — 24KB
- 0001104659-24-079255.txt ( ) — 186KB
- enzn-20240702.xsd (EX-101.SCH) — 3KB
- enzn-20240702_lab.xml (EX-101.LAB) — 33KB
- enzn-20240702_pre.xml (EX-101.PRE) — 22KB
- tm2419328d1_8ka_htm.xml (XML) — 3KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations. The Board of Directors (the "Board") of the Company has established September 26, 2024, as the date for the Company's Annual Meeting. The Board also established August 7, 2024, as the record date for the Annual Meeting. Due to the fact that the Company is now holding its Annual Meeting more than 25 days from June 8, 2024, the Company is providing the due date for submission of any qualified stockholder proposal or director nominations. In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Exchange Act, and the Company's bylaws (the "Bylaws"), the deadline for receipt of stockholder proposals or nominations for inclusion in the Company's proxy statement for the Annual Meeting pursuant to Rule 14a-8 will be no later than July 12, 2024 and must be received by the Company's secretary at 20 Commerce Drive, Suite 135, Cranford, New Jersey, 07016 no later than such date. Stockholder proposals must comply with all of the applicable requirements set forth in the rules and regulations of the Securities and Exchange Commission, including Rule 14a-8 under the Exchange Act and the Bylaws.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZON PHARMACEUTICALS, INC. (Registrant) Date: July 11, 2024 By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary